HROW Harrow36.40-2.82 (-7.2%)
HROW Harrow39.40-14.19 (-26.5%)
Premarket Decliner
HROW Harrow53.59-0.59-1.1%
Premarket:45.60-7.99 (-14.9%)
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Globe NewswireTue, 3-Mar 7:00 AM
HROW Harrow52.89-1.29 (-2.4%)
HROW Harrow53.53-0.65 (-1.2%)
HROW Harrow44.00+3.06 (+7.5%)